Human papillomavirus vaccination among childhood cancer survivors: A scoping review Authors: Pragya Gautam Poudel, Julia Brown, Tara M Brinkman, Casey L Daniel, Melissa M Hudson, James L Klosky, Kirsten K Ness, Heather M Brandt Published: 2025 ABSTRACT ABSTRACTChildhood cancer survivors are at increased risk for human papillomavirus (HPV) cancers yet are less likely to be vaccinated against HPV than the general population. This scoping review identified studies describing barriers, facilitators, and strategies to improve HPV vaccination in this vulnerable population. We searched PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science to identify full-length studies, published in English, from July 2006 to June 2024. We excluded survivorship studies unrelated to HPV vaccination and non-empirical studies (e.g. commentaries). Twenty studies were identified. Multi-level barriers reported occurred in patients- (e.g. vaccine safety-concerns), provider- (e.g. inconsistent guidelines), and system-levels (e.g. lack of vaccine availability). The primary facilitator was the health care provider’s recommendation. Potential strategies for increased vaccination included clear recommendations and digital reminders. This review provides valuable insights for developing strategies to improve HPV vaccination coverage and reduce the risk of HPV-related cancers among childhood cancer survivors.KEYWORDS: HPV vaccination, childhood cancer survivors, barriers, facilitators, health care providers Introduction The five-year survival rate for childhood cancers has increased from 58% in the 1970s to 85% today.1 This improvement in survival is primarily attributed to the development of innovative and effective cancer-directed therapies. It has been estimated that more than 500,000 childhood cancer survivors (cancer survivors, hereafter), who have survived five or more years after diagnosis of cancer, are currently living in the United States (U.S.).2 Concurrent with improvement in survival, cancer survivors face an elevated risk of developing treatment-associated chronic health conditions, including subsequent cancers. They also have an increased risk of developing human papillomavirus (HPV)-associated cancers in adulthood, presumably attributed to treatment-related compromised immune systems.3 Both male (oropharyngeal, anal, penile cancer) and female (cervical, oropharyngeal, anal, vaginal, and vulvar cancer) cancer survivors are vulnerable to HPV-related malignancies. Compared with the age- and sex- matched general U.S. population, female and male childhood and young adult cancer survivors have 1.4-fold and 2.5-fold, respectively, higher risk of developing HPV-associated malignancies.3 Evidence shows that the median age for HPV-associated subsequent malignant neoplasms among these cancer survivors is 31 years, and ranges from 10 to 56 years,4 which highlights the persistent threat of HPV-associated cancers into adulthood. Fortunately, the majority of these HPV-associated malignancies can be prevented through timely HPV vaccination.5 The Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers recommend a three-dose HPV vaccine series for all childhood cancer survivors, regardless of their age at the first dose of the HPV vaccine, beginning 6 months after the completion of cancer-directed therapy.6 This recommendation aligns with the Advisory Committee on Immunization Practices (ACIP) guidance, which recommends a three-dose series for immuno-compromised individuals.7 Evidence shows that immunogenicity and safety of the three-dose series of the HPV vaccine among cancer survivors are similar to the general population.8 However, HPV vaccination coverage among childhood cancer survivors is lower compared to the general population (i.e., 23.8% vs. 40.5%, respectively).9 Some reasons for lower HPV vaccination in cancer survivors include vaccine hesitancy, safety concerns, lack of adequate health insurance coverage, and lack of health care provider recommendations.10 Lower HPV vaccination coverage among these cancer survivors is highly concerning, particularly in the context of their elevated risk for subsequent malignancies. Prior reviews evaluating health behaviors among cancer survivors have largely focused on diet, physical activity, alcohol use, and smoking.11–13 In contrast, few studies have described cancer survivors’ behaviors related to HPV vaccination as an effective cancer prevention measure.14,15 Previous reviews, conducted only a few years after the HPV vaccine, was formally approved by the Food and Drug Administration (FDA) in the U.S. (2006 for females and 2009 for males), did not systematically focus on behavioral determinants, namely barriers and facilitators, pertaining to HPV vaccination.11–13 Furthermore, comprehensive strategies to increase HPV vaccination coverage among cancer survivors were not and have not been addressed. Understanding the barriers and facilitators to HPV vaccination will inform the development of tailored strategies for improving HPV vaccination coverage among cancer survivors. Thus, our study aimed to address this gap by conducting a systematic scoping review of the scientific literature and identifying studies describing barriers and facilitators of HPV vaccination among childhood cancer survivors. Additionally, we aimed to identify evidence – based interventions, programs, or strategies that improved in HPV vaccination initiation and completion among these cancer survivors. The results of this review will best position clinicians and researchers to develop, test and implement vaccine interventions for cancer survivors, with the goal of reducing late-stage HPV-associated cancers in this high-risk group of cancer survivors. Methods We performed a scoping review to comprehensively explore and identify available studies on barriers and facilitators to HPV vaccination, as well as existing programs or strategies aimed at improving HPV vaccination coverage among cancer survivors. A scoping review approach was chosen as it provides a systematic and replicable strategy to rigorously evaluate the available evidence and identify any knowledge gaps as targets for future research.16 We adhered to the scoping methodology outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), ensuring a rigorous and transparent approach to guide the review process in selecting the relevant studies.17 This included defining eligibility criteria, conducting a comprehensive search of multiple databases, selecting relevant studies, and extracting key data on barriers, facilitators, and strategies related to HPV vaccination. Search strategy We comprehensively searched PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science between 7/1/2006 (the year of FDA licensure of HPV vaccine in the U.S.) to 6/14/2024 to identify qualifying studies. The combination of keywords and MeSH terms were used to search the original studies as shown in Table 1. Briefly, we used following keywords and MeSH terms: (((((Human papillomavirus) OR (Human papillomavirus vaccines)) OR (HPV vaccination)) OR (vaccination [MeSH Terms])) AND (((((((Childhood cancer survivors) OR (Survivors of childhood cancer)) OR (Pediatric survivors)) OR (Cancer survivors)) OR (Young survivors)) OR (Adolescent and young adult survivors)) OR (AYA survivors))) AND (((Interventions) OR (Programs)) OR (Strategies)). The last search was performed on June 14, 2024. Table 1.Search strategy using PubMed.1)Human papillomavirus OR Human papillomavirus vaccines OR HPV vaccination OR vaccination [MeSH Terms]2)Childhood cancer survivors OR Survivors of childhood cancer OR Pediatric survivors OR Cancer survivors OR Young survivors OR Adolescent and young adult survivors OR AYA survivors3)Interventions OR Programs OR Strategies4)Combined above 1 to 3 steps:(((((Human papillomavirus) OR (Human papillomavirus vaccines)) OR (HPV vaccination)) OR (vaccination [MeSH Terms])) AND (((((((Childhood cancer survivors) OR (Survivors of childhood cancer)) OR (Pediatric survivors)) OR (Cancer survivors)) OR (Young survivors)) OR (Adolescent and young adult survivors)) OR (AYA survivors))) AND (((Interventions) OR (Programs)) OR (Strategies))5)Used following filters: Full text, English, published from 2006–2024 Search strategy using PubMed. Eligibility criteria We included original quantitative and qualitative studies focused on barriers and facilitators influencing HPV vaccination among cancer survivors (diagnosed with cancer before age 18 years and completed cancer-directed therapy), studies focusing on programs or strategies to improve HPV vaccination coverage among cancer survivors, studies conducted in the U.S., and full text studies published in the English language. We excluded articles that focused on cancer survivorship other than HPV vaccination, publications that did not report original research results (e.g., commentaries, editorials, protocols, reviews), or were not full-length articles, such as conference meeting abstracts. Selection procedure Studies were selected for inclusion using the following: In step 1, the literature searches provided 388 studies (189 in PubMed, 122 in CINAHL, and 77 in Web of Science); In step 2, 45 duplicates were removed providing 343 studies for further assessment; In step 3, titles and abstracts were screened, with 32 studies relevant to the inclusion criteria retained. In step 4, full-text studies were assessed, and 20 studies were included in this review (shown in Figure 1). We found only two meeting abstracts that focused on programs or strategies.18,19 However, we did not find full-length, peer reviewed, studies focusing on strategies to improve HPV vaccination coverage among cancer survivors. As a result, we only included studies focusing on barriers and facilitators influencing HPV vaccination coverage among cancer survivors. Two independent reviewers (first and second authors, PGP and JB, respectively) screened the titles and abstracts of all studies that met the eligibility criteria. The full text of the potentially relevant studies were also independently screened by these two reviewers (PGP and JB). Any disagreements during the review process were resolved by discussion and the opinion of the senior author (HMB). PRISMA flow diagram for study selection. Data extracted from the original studies included the authors’ details, publication year, study aims, demographic characteristics of the participants, types of cancer diagnosed, age at cancer diagnosis, duration of cancer-therapy completion, methods used including study design, study findings related to barriers, facilitators and potential strategies, and other key study highlights (Tables 2 and 3). The first author (PGP) conducted the data extraction, and another author (JB) carefully reviewed the extracted data using the full texts of respective studies. Table 2.Showing characteristics of the studies regarding HPV vaccination in childhood cancer survivors.Author (publication year)Study aim(s)Study sampleRace/ethnicityParticipants’ age (years)Type of cancer diagnosedAge at cancer diagnosis (years)Duration since cancer-therapy completion (years)Survivor or caregiver levelKaddas et al. (2023)24To assess HPV vaccination initiation and completion rates among pediatric, adolescent, and young adult cancer survivors within Utah’s two primary healthcare systems, compared with cancer-free controls; to identify differences in initiation and completion of HPV vaccination based on demographic & clinical factors.Total survivors = 1579; controls = 4513Survivors:Females = 843Males = 736Controls:Females = 2353Males = 2160Survivors:Non-Hispanic White = 1259; Hispanic/Latino = 244 Other = 76Controls:Non-Hispanic White = 3855 Hispanic/Latino = 440Others = 218Survivors:Mean (SD) = 14.8 (4.3) and range = 9–21Controls:Mean (SD) = 14.7 (4.3) and range = 9–21Survivors:Leukemia = 367Lymphoma = 238CNS = 234Other solid tumors = 282Sarcoma/bone = 211Epithelial = 247Survivors:0–4 years = 3835–8 years = 2119–12 years = 27413–16 years = 27517–21 years = 436NARahim et al. (2023)29To assess the HPV vaccination rates among adolescent and young adult (AYA) cancer survivors and individuals with sickle cell disease (SCD). Also, aimed to understand the beliefs and attitudes of AYA patients and caregivers regarding HPV vaccination, as well as vaccine hesitancy factors.Total:AYA = 21[Females = 13; Males = 8]Caregiver = 48 [Females = 38; Males = 10]Ethnicity of AYA:White = 8; Asian = 1; African American = 11; Latino and White = 1Ethnicity of caregiver:White = 22; Asian = 1; African American = 23; Latino = 2Average age of child by caregivers, mean (range) (years) = 14.5 (9–21)AYA, mean (range) (years) = 19 (18–21)Caregiver report on child’s diagnosis:Sickle cell disease = 25Oncologic diagnosis = 23AYA report:Sickle cell disease = 11; Oncologic diagnosis = 10NANACherven et al. (2022)10To understand the reasons for refusal of HPV vaccine among young cancer survivors.Total = 301[Females = 137Males = 164]Overall:Non-Hispanic White = 223; Non-Hispanic Black = 46; Hispanic = 22; Other = 10Range = 9–26 years9–17 = 20618–26 = 95Survivors:Leukemia/lymphoma = 160Solid tumor = 141NAMean (SD) = 2.9 (1.2)Median (range) = 2.9 (1.0–5.0)Garcia et al. (2022)22Examined factors related to HPV vaccine uptake among childhood cancer survivors from Western New York over 13 years following the introduction of HPV vaccines.Total = 284[Females = 142Males = 142]Overall:Non-Hispanic White = 228Black/African American = 20Asian = 7Hispanic = 7Other/unknown = 22Range = 9–26 yearsSurvivors:Female:Leukemia/lymphoma = 72Brain/CNS tumor = 14Solid tumor = 56Males:Leukemia/lymphoma = 84Brain/CNS tumor = 13Solid tumor = 45Survivors:Median (Range):Female:4.5 (2.5, 7.0)Male:4.8 (2.8, 6.8)Median time to initiate:Females = 5.5Males = 5.7Ramsay et al. (2022)30Evaluated whether survivors are at higher risk of missed opportunities for concomitant HPV vaccination.Survivors = 327 [Females = 144; Males = 183]Controls = 1911 [Females = 910; Males = 1001]Survivors:Non-Hispanic White = 253; Other = 74Controls:Non-Hispanic White = 1569; Other = 342Survivors:Mean (SD) = 10.6 (2); range = 9–16Controls:Mean (SD) = 11.2 (2); range = 9–16Survivors:Leukemia = 113; Lymphoma = 26; CNS = 70; Solid Tumors = 83; Sarcomas/bone = 26; Epithelial= ≤10Survivors:0–4 years = 1925–9 years = 135NAWaters et al. (2022)32Explored HPV vaccination experiences and preferences among young adult cancer survivors and caregivers of childhood cancer survivors.AYA survivors = 10 [Females = 6; Males = 4]Caregivers = 10[Females = 9; Males = 1]AYA survivors:Non-Hispanic White = 9; Other = 1Caregivers:Non-Hispanic White = 8; Other = 2AYA survivors:Mean (range) = 21.1 (18–23)Caregivers:Mean (range):30–39 years = 240–49 years = 650–59 years = 2Leukemia = 5; CNS tumor = 3; Sarcoma = 5; Lymphoma = 7NANAWarner et al. (2020)31To determine whether the intent to restart vaccines after treatment was greater among caregivers who had received a recommendation about vaccinations from their child’s provider. Also, to explore caregiver’s hesitancy and barriers to restarting vaccines.Total = 145 [Females = 116; Males = 27]Race:White = 129Other = 13Ethnicity:Non-Hispanic = 124Hispanic = 15Caregivers’ age (years):18–29 = 1430–39 = 7940–49 = 3950–59 = 12Survivors:Leukemia = 54Brain/CNS = 21Lymphoma = 26Other = 44Survivors:Age of child diagnosed with cancer: ≤17 years0–4 years = 535–9 years = 3910–14 years = 3315–17 years = 20Completion of cancer therapy: range = 3–36 monthsYork et al. (2020)33To examine survey data from young cancer survivors & their parents to understand patient-level factors associated with lack of healthcare provider recommendation for vaccination.Total survivors = 955[Females = 436; Males = 519]Non-Hispanic White = 628; Non-Hispanic Black = 151; Hispanic = 112; Other = 64Range (years) = 9 to 269–17 years = 589; 18–26 years = 366Leukemia = 344; Lymphoma = 219; Solid tumor/CNS tumor = 392NAMean (SD) = 32.8 (14.7) monthsMedian (range) = 33.5 (12–60) monthsCastellino et al. (2019)20To estimate the population-based incidence of HPV vaccination after childhood cancer.Total sample = 879[Females = 428; Males = 451]Females:Non-Hispanic/White = 342; Black = 53; Asian = 3; Hispanic = 24; Other/unknown = 7Males:Non-Hispanic/White = 347; Black = 65; Asian = 8; Hispanic = 26; Other/unknown = 5Range = 11–26 yearsSurvivors:Leukemia = 242Lymphoma = 148Solid tumor = 319Thyroid cancer = 31Melanoma = 24Other cancer = 115Survivors:Mean (SD):Females = 10.3 (7.4)Males = 8.8 (6.7)NACherven et al. (2019)21To determine relationship between HPV vaccine intent and subsequent vaccine initiation in cancer survivors by linking data from a cross-sectional survey with state-based immunization registry.Total sample = 135[Females = 66; Males = 69]Overall:Non-Hispanic White = 87; Other = 48Median (range) = 15.40 (9.04–25.77) yearsSurvivors:Leukemia/lymphoma = 78Solid tumor = 57Survivors:Median (range) = 10.30 (2.41–21.43) yearsMedian (range) = 3.05 (1.04–4.99) yearsKirchhoff et al. (2019)25To understand HPV vaccine knowledge and beliefs among caregivers for their child, evaluate the caregivers’ intentions regarding the likelihood of having their child with cancer receive HPV vaccine. Additionally, reported on factors associated with HPV vaccination including providers discussion on vaccination strategies after the completion of cancer treatment.Total = 145[Females = 116; Males = 27]Race:White = 129; Other = 13Ethnicity:Non-Hispanic = 124; Hispanic = 15Caregivers’ age (years):18–29 = 1430–39 = 7940–49 = 3950–59 = 12Survivors:Leukemia = 54Brain/CNS = 21Lymphoma = 26Other = 44Survivors:0–4 years = 535–9 years = 3910–14 years = 3315–17 years = 20NAKlosky et al. (2017)9To estimate the prevalence of HPV vaccine initiation in cancer survivors versus the US population and examined predictors of non-initiation.Total survivors = 982[Females = 446; Males = 536]Non-Hispanic White = 643 Hispanic = 120African American = 153 Other = 66Age range = 9–269–12 = 30313–17 = 30318–26 = 376Leukemia = 355Lymphoma = 224Solid tumor = 403Mean (SD) = 12.1 (5.3)Median (range) = 12.2 (0–24.7)Mean (SD) = 2.7 (1.2)Median (range) = 2.7 (1.0–5.0)Klosky et al. (2016)28To estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes.Total = 212[Survivors = 114; controls = 98][All female participants]Survivors:White = 85Non-White = 29Controls:White = 42Non-White = 56Range = 18–26Survivors:Mean (SD) = 21.18 (2.48)Controls:Mean (SD) = 20.65 (2.29)Survivors:Leukemia/Lymphoma = 53; Brain/CNS tumors = 25; solid tumors = 360–4 years = 165–9 years = 1610–14 years = 5415–19 years = 28NAKlosky et al. (2015)27To estimate the HPV vaccination initiation and completion across females surviving childhood cancer, and to identify sociodemographic and cancer-specific factors associated with HPV vaccination initiation and completion.Total = 344[All female participants]Pre-adolescents (9–13 years):White = 92Nonwhite = 21Adolescents (14–17 years):White = 83Nonwhite = 34Young adults (18–26 years):White = 85Nonwhite = 29Mean (SD):Pre-adolescents = 10.9 (1.43)Adolescents = 15.6 (1.13)Young adults = 21.2 (2.48)Pre-adolescents:Leukemia/lymphoma = 45; Brain/CNS = 18; solid tumors = 50Adolescents:Leukemia/lymphoma = 43; Brain/CNS = 26; solid tumors = 48Young adults:Leukemia/lymphoma = 53; Brain/CNS = 25; solid tumors = 36NANAKlosky et al. (2013)26To estimate the prevalence of HPV vaccination among childhood cancer survivors and identify factors associated with HPV vaccine initiation and completion.Total maternal caregiver = 300[Survivors = 230; controls = 70]Race of caregivers:Survivors:White = 175; Non-White = 55Controls:White = 54; Non-White = 16Caregivers’ age:Survivors:18–40 = 10741–62 = 123Controls:18–40 = 3141–62 = 39Survivors’ diagnosis:Leukemia/lymphoma = 88Brain/CNS tumor = 44Solid tumor = 98Survivors age at diagnosis:0–4 years = 1735–8 years = 489–12 years = 9 Hoffman et al. (2012)23To determine the prevalence of HPV vaccination among female pediatric cancer survivors, age 11–18 years, at Texas Children’s Hospital.Total survivors = 66(all females)White/non-Hispanic = 31; White/Hispanic = 23; Black = 6; Asian = 3; Other = 2Median age = 14 years11–12 = 2113–17 = 3618 = 9Survivors:Leukemia = 31Hodgkin-lymphoma = 3non-Hodgkin lymphoma = 6 Brain/spine tumor = 6Kidney tumor = 9 Neuroblastoma = 4 Soft tissue sarcoma = 2 Other = 5Survivors:≤5 years = 416–10 years = 1611–13 years = 3NAAuthor (publication year)Study aimStudy sampleRace/EthnicityAge (years)Area of specialtyYears in practiceNumber of survivors seen by providerProvider-levelGarcia et al. (2023)34To assess the perceived barriers, opportunities, and roles pertaining to HPV vaccine delivery among PAYA cancer care providers.Total = 49 Females = 33Males = 12Decline/missing = 4Non-Hispanic White = 36Asian/pacific islander = 7Black/African American = 1Hispanic = 1Mean (SD) = 47 (12.4)Oncology or hematology physician = 37Oncology or hematology fellow = 3Oncology or hematology nurse fellow/practitioner = 6Less than 10 = 1510 or more = 31Patients seen per day: <15 = 41≥15 = 4Miller et al. (2023)36To assess physician and nurse practitioner views regarding HPV vaccination, with a focus on access and barriers to providing HPV vaccination in pediatric hematologic and oncology practices (PHO), via in-depth interviews.Total = 20[Females = 13 Males = 7]White = 17; African American = 2; Latinx/Hispanic = 1Age (years):20–30 = 131–40 = 1241–50 = 551–60 = 061–70 = 2General Hematology/Oncology = 4; Oncology (solid tumor/lymphoma) = 4; Oncology (CNS tumors) = 2; Oncology (leukemia) = 1; Oncology (survivorship) = 2; Oncology (BMT) = 2; Hematology (hemoglobinopathies) = 3; Hematology (hemostasis/thrombosis) = 20–5 years = 96–10 years = 411–20 years = 5 >21 years = 2 (Continued). Showing characteristics of the studies regarding HPV vaccination in childhood cancer survivors. (Continued). Table 3.Showing methods, findings, and highlights of the included studies regarding HPV vaccination in childhood cancer survivors.Author Date/TitleMethodsFindingsHighlight of the studySurvivor or caregiver levelKaddas et al. (2023)24Used the Utah Population Database (UPDB), a comprehensive statewide database containing linked demographic, clinical, and vital records. Vaccination records were obtained from Utah’s Statewide Immunization Information System. HPV vaccination initiation (1-dose) and completion (3 doses) rates were assessed.Gender differences: male survivors were 50% less likely to initiate or complete the vaccination than female survivors.Survivors from rural location were 50% less likely to initiate and 80% less likely to complete the vaccination than survivors from urban location. Lower initiation in rural survivors (IIR = 0.5, 95% CI: 0.26–0.84) than urban.Cancer diagnosis type: survivors diagnosed with a solid tumor were almost two times more likely to initiate vaccination than diagnosed with epithelial cancer.Between survivors and controls, Hispanic survivors were 50% less likely to initiate or complete the vaccination than Hispanic individuals in controls.Highlighted disparities in vaccination according to survivors’ gender, location, and type of cancer diagnosis.Also, identified lower initiation for Hispanic survivors, despite the higher rates in the general Hispanic population suggested potential healthcare access and survivorship care disparities.Rahim et al. (2023)29Used retrospective data and qualitative interviews to examine HPV vaccination status among AYA with childhood cancer history and sickle cell disease (SCD). Vaccination records were obtained from the Immunization Registry. Qualitative interviews were conducted with caregivers and AYA survivors (9 to 21 years).Misconceptions of HPV vaccine was prevalent among caregivers, including belief that it is primarily for females or linked to sexual activity.Survivors’ knowledge gap regarding the HPV vaccine.Strong recommendations and counseling from trusted specialty group.Emphasized critical role of physician counseling in influencing HPV vaccination decisions.Showed need for targeted communication strategies to address knowledge gaps and enhance HPV vaccine uptake.Cherven et al. (2022)10HPV vaccination in cancer survivors was examined among survivors aged 9–26, 1–5 years post-cancer treatment completion. Involved survivors/parents who declined participation, and their verbatim responses were coded and analyzed using a qualitative approach.71.4% of 301 survivors refused due to safety concerns, vaccine hesitancy, external influences, information deficits, and health beliefs/family decisional processes.Females were more likely to refuse for reasons related to health beliefs/family decisional processes (OR = 2.08, p = .022) and less likely to refuse due to external influences (OR = 0.43, p = .035) than males.Five primary reasons for HPV vaccine refusal among young cancer survivors: safety concerns, vaccine hesitancy, external influences, vaccine-related information deficits, and health beliefs and family decision making process.Garcia et al. (2022)22Performed retrospective analysis of electronic medical records (EMR) for childhood cancer survivors treated at Roswell Park Comprehensive Center and the Oishei Children’s Hospital Cancer and Blood Disorder Program. They were matched with their immunization records from the New York State Immunization Information System.Gender differences: Time to initiate HPV vaccine was 5.7 years for males and 5.5 years for females. Those who initiated, 43.3% males and 55.1% females completed three-dose series, with males taking longer time to complete the vaccination.Age at cancer diagnosis: older age (6–9 years), vs. < 6 years, were more likely to initiate HPV vaccination for male survivors [HR = 2.13, p = .04] and female [HR = 1.15, p = .609]; however, for female the finding was not significant.Reasons for less likely to initiate the vaccine: Being 18–26 years old at vaccine eligibility (HR = 0.04, 95% CI 0.01–0.16 and males who received blood transfusions during treatment (HR = 0.38, 95% CI 0.18–0.83).Difference in HPV vaccination according to gender, age at vaccine eligibility, types of cancer diagnosed, and cancer treatment.Ramsay et al. (2022)30Statewide (Utah) population data. Included survivors from the Utah Cancer Registry, diagnosed from 2000 to 2016. Missed opportunities- defined as a vaccine encounter where the HPV vaccine was not administered, although eligibility criteria were met. Follow-up for the participants started at their first vaccine encounter following eligibility.Among survivors, chemotherapy treatment was associated with a higher rate of missed opportunities (IRR = 1.35, 95% CI: 1.12, 1.62).Age at diagnosis [i.e., diagnosed at older age: IRR = 1.04, 95% CI: 1.02, 1,06] and survivors living in rural area [IRR = 1.27, 95% CI: 1.09, 1.49] were also associated with higher rates of missed opportunities.Higher missed opportunities related to HPV vaccination in cancer survivors suggests need of interventions to increase HPV vaccination among survivors, especially, from rural area.Waters et al. (2022)32Explored factors influencing HPV vaccination among cancer survivors (18–26 years) and caregivers of young survivors (9–27 years), who completed treatment between 2013–2018. Participants were recruited from Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI) through clinic schedule screenings.Participants expressed insufficient information about the HPV vaccine, worries about safety and side effects for cancer survivors, and concerns about its appropriateness for cancer survivors.Recommendations from trusted providers, including oncologists, were crucial for vaccination initiation.Most participants preferred to receive recommendations from their cancer team, typically their oncologist.Reminders, preferably digital messages, were mentioned to be helpful, with multimedia messages.Highlighted the important role of oncology providers in providing information regarding the appropriateness of the vaccine for cancer survivors.Warner et al. (2020)31Conducted at the Intermountain Healthcare’s Primary Children’s Hospital. Investigated caregivers’ intentions to restart vaccination for pediatric cancer survivors. Eligible participants were English-speaking caregivers with a child who completed cancer treatment. The survey covered vaccine experiences, preferences, caregiver demographics, and healthcare factors.Caregivers without intent to vaccinate their child held fewer beliefs in protective and necessary aspects of vaccines than those with vaccine intentions.Recommendations from healthcare providers increased the likelihood of vaccine intention (oncologist RR = 1.65, p < .01, PCP RR = 1.51, p < .01).Greater time since diagnosis was associated with vaccine intention.Barriers included uncertainty about needed vaccines, concerns about safety and side effects.Highlighted that the caregivers who had discussed vaccines with a provider (either with oncology or primary care) were more likely to initiate vaccination.Emphasized the importance of HPV vaccination recommendations from healthcare providers.York et al. (2020)33The survey included survivors: 18–26 years or parents of survivors of 9–17 years, available in English and Spanish, gathered sociodemographic information, vaccine-related history, perceived insurance coverage for the HPV vaccine, attitudes and health beliefs related to vaccination. Also, explored factors associated with the absence of the provider’s recommendations.73% reported a lack of healthcare provider recommendation for the HPV vaccine.Perceived lack of insurance coverage (OR = 4.0, p < .001), male sex (OR = 2.8, < 0.001), and decreased parent-survivor communication (OR = 1.6, p = .003), were identified as factors for less likely receiving a provider recommendation for the vaccine.Age-stratified analyses showed lack of recommendation, with perceived lack of insurance and male sex remaining significant in both younger and older participants.Highlighted the importance of insurance coverage, adequate and timely communication, and demographic including gender-specific considerations in healthcare provider recommendations for HPV vaccination among young cancer survivors.Castellino et al. (2019)20Pediatric and young adult cancer survivors identified in the Institutional Comprehensive Cancer Center registry were linked to the North Carolina Immunization Registry (NCIR). Uptake of vaccine assessed in females and males born between Jan 1, 1984 and Dec 31, 2002, aligning with ACIP age recommendations for HPV vaccination.Gender differences: age at vaccine initiation, mean (SD): for female was 15 (2.9) years and for male was 15.5 (3.3) years. Among < 18 years: HPV vaccine initiation incidence among females was 48.1% at 8.2 years, and males was 29.2% at 5.0 years among those < 18 years. Among those ≥18 years: 6.2% among females at 8.1 years and 2.0% among males at 4.2 years. Among those who initiated, 53% females and 43% males completed a 3-dose series.Younger age at cancer diagnosis and shorter interval from diagnosis to vaccine eligibility were more likely to initiate the vaccination.Age at cancer diagnosis emerged as a significant predictor, with younger survivors more likely to initiate vaccination.Time from cancer diagnosis negatively influenced vaccine initiation, emphasizing the need for timely intervention during pediatric oncology and survivorship care.Cherven et al. (2019)21Data collected from the HPV vaccine in cancer survivors’ study (HPVCSS) collected between 2012 and 2014 at Emory Children’s Healthcare of Atlanta. Cancer survivors aged 9–26 years. Surveys completed by participants or their parents and clinical details extracted from the medical records.Factors for increased HPV vaccine intent included provider recommendation (OR = 5.0; p = .01), positive attitude toward vaccines (OR = 4.8; p < .001), and perceived severity of HPV-related illness (OR = 3.5; p = .02).The intent to receive the HPV vaccine is influenced by healthcare provider recommendations and positive attitudes toward the vaccines.Kirchhoff et al. (2019)25Included caregivers aged ≥18, who had a child diagnosed with cancer aged= < 17 and had completed cancer treatment 3–36 months prior at Primary Children’s Hospital. Caregivers were approached in person at follow-up appointments and requested them to complete a survey and participate in focus group discussion.Common reasons for refusal were not having enough information on HPV vaccine (25.2%), child not being the right age (22.7%), and worries about side effects (21.9).Enough information from providers regarding vaccine and side effects (relative risk (RR) = 1.85, 95% CI 1.16–2.94) and recommendations regarding vaccines after cancer treatment (RR = 1.35, 95% CI: 1.06–1.72) showed greater caregiver intention to get the HPV vaccine for their child.Enough information (vaccine, benefits, and side effects) from providers positively influenced caregivers’ intention to vaccinate their child.Klosky et al. (2017)9Cross-sectional survey, identified from five National Cancer Institute- designated Comprehensive Cancer Centers. HPV vaccine initiation rates among survivors were compared with age-, sex- and year-matched US population peers using data from the National Immunization Survey-Teen (NIS-Teen; ages 13–17 years) and National Health Interview Survey (NHIS; ages 18–26 years).Predictors of non-initiation of HPV vaccine included lack of provider recommendation (OR = 10.8, p < .001), survivors’ perceived lack of insurance coverage (OR = 6.6, p < .001), male sex (OR = 2.9, p < .001), endorsement of vaccine-related barriers (OR = 2.7, p < .001), and younger age (i.e. 9–12 years vs. 13–17 years: OR = 3.7, p < .001).Among those who received a provider recommendation, predictors of vaccine non-initiation included lack of insurance coverage (OR = 7.5, p < .001) and younger age (OR = 5.0, p < .001).Predictors for non-initiation included lack of provider recommendation, lack of insurance, endorsement of vaccine-related barriers and younger age.Highlights the importance of provider recommendation.Klosky et al. (2016)28Young women surviving childhood cancer were recruited from the ACT- clinic at SJCRH. 114 total survivors and 98 controls were included. During their visit at the clinic, they participated in 15–30 min survey related to their understanding about HPV, severity of HPV, barriers to initiating vaccine, benefits and efficacy of vaccine and their self-efficacy.Physician recommendation (OR = 11.24, p < .001) and familial HPV communication (OR = 7.28, p = .01) were positively associated with vaccine initiation.Perception of vaccine benefit was associated with vaccine completion (OR = 10.55, p = .02), whereas perception of vaccine severity was associated with non-completion (OR = 0.14, p = .02).Highlighted that the physician recommendation for HPV vaccine as a strong predictor of vaccine initiation and completion in cancer survivors.Klosky et al. (2015)27Participants recruited from the ACT- clinic at SJCRH. A total of 230 mothers and 114 young adult females with a history of childhood cancer participated. The participants were divided into preadolescents (9–13 years), adolescents (14–17 years), and young adults (18–26 years) for analysis. Sociodemographic and medical factors were assessed through questionnaires and medical records.Initiation rate varied by age group, with preadolescents having lower initiation rate (19.5%) than adolescents (45.3%) and young adults (38.6%).Older age at diagnosis (≥12 years) [OR = 0.28, p = .01] was associated with lower vaccine initiation and provider recommendation [OR = 11.96, p < .001] was associated with higher vaccine initiation.Regarding vaccine completion: non-White participants were less likely to complete [OR = 0.17, p = .01], and receiving physician recommendation [OR = 7.54, p = .03] were more likely to complete.Highlighted the age group disparities with the preadolescents showing lower HPV vaccine initiation rates than adolescents and young adults.Physician recommendation emerged as a key predictor for vaccine initiation across all age groups.Klosky et al. (2013)26Maternal caregivers of daughters with history of childhood cancer were recruited from the After Completion of Therapy (ACT) Clinic at the St. Jude Children’s Research Hospital (SJCRH). Each mother provided contact details for up to five controls with similar demographics. Participants completed surveys covering sociodemographic factors, medical history, HPV knowledge and communication, and health beliefs.Older daughter’s age (OR = 5.82; 95% CI: 2.00–16.91) and physician recommendation (OR = 6.54; 95% CI: 2.56–16.73) were associated with increased vaccine initiation.Mothers who perceived greater barriers (financial or religious, fears that vaccine promoting sexual activity, general lack of support for vaccination) were less likely to start the vaccination for their daughters.Among those who initiated, risk factors for noncompletion included being non-White (OR = 0.26, p = .032) and perceiving barriers to vaccination (OR = 0.21, 0.015).Older age of the daughter and receiving recommendation from healthcare provider showed increased vaccine initiation.Hoffman et al. (2012)23Survey was distributed to parents of female pediatric cancer survivors (≥5 years from diagnosis and ≥2 years off therapy). The survey covered demographics, cancer history, medical care utilization, education, sexual history, and beliefs about HPV vaccination.Age differences: overall rate for HPV vaccination (1 or more) was 5% among ages 11–12 years, 36% for 13–17 years, and 78% among 18 years.Hesitancy about HPV vaccine safety and side effects.Factors positively associated with vaccination: age ≥13, report of sexual activity, and discussed about HPV vaccination with health care providers.Highlighted that the survivors ages ≥13 years were more likely to initiate HPV vaccine series than their younger counterparts.Provider-levelGarcia et al. (2023)34A web-based survey, combing closed- and open-ended items, was administered. Survey included questions related to HPV infection and vaccine knowledge, vaccine communication and willingness, and provider-reported barriers and opportunities, with responses measured on a Likert scale. Also, three open-ended questions were included to gather in-depth insights into barriers, opportunities, and roles.47% providers mentioned communication with patients about HPV vaccination, 69% expressed willingness to become involved in vaccine delivery.Perceived barriers included roles outside clinical care, competing priorities, provider knowledge gaps, and patient- and family- related factors (e.g., patient being too young for vaccination, hesitancy, knowledge gap, family preference), and system-level (e.g., HPV vaccine not included in clinical setting like COVID-19 or influenza vaccine, access to HPV vaccine, delays in processing HPV vaccine).Providers expressed HPV vaccine delivery to be under the system (e.g., having it available, sending EMR reminders).Opportunities to collaborate between oncology providers and primary care providers.Highlighted providers’ willingness to play active roles in HPV vaccine delivery.Key potential areas identified included access and coordination of vaccine administration, engaging in cancer prevention education, and advocating for HPV vaccination during transitions in care.Miller et al. (2023)36A state-wide study of providers, in the state of Indiana, were invited to participate in a 30-min interview. The interview assessed providers’ attitudes toward vaccination, including HPV vaccination. 18 physicians and 2 nurse practitioners completed the one-on-one qualitative interview. The interviews (January 2021 to March 2021) addressed provider attitudes toward the HPV vaccine, concerns or misconceptions from patients and their families, and barriers to HPV vaccination in pediatric hematology/oncology clinics.90% recognized the importance of HPV vaccination for their patient population, with 65% expressing no concerns about the vaccine.The primary motivation for recommending HPV vaccination was cancer prevention (80%).75% believed that the responsibility for HPV vaccination should fall under the PCP care.Barriers: patient-level: concerns about promoting sexual activity and worries about side effects; clinician-level: lack of updated information and awareness of available vaccines; system-level: time constraints, inadequate nursing/medical assistant resources, difficulties accessing vaccine records, vaccine accessibility, storage limitations, cost, and reimbursement challenges.Highlighted that majority providers recognized the importance of HPV vaccination; however, clinicians faced challenges in accessing information, vaccine availability, and time constraints.Showed importance of multi-level interventions, including patient-level, provider-level, and system-level, to improve HPV vaccination coverage.Waters et al. (2023)37Utilized Theoretical Domains Framework (TDF) and Capability, Opportunity, Motivation, and Behavior (COM-B) model to investigate the implementation determinants of introducing HPV vaccination into the oncology setting. Conducted at the Primary Children’s Hospital and Huntsman Cancer Institute in Salt Lake City and the study included 24 oncology providers. Through the qualitative analysis of interview transcripts, the research identified themes related to capability, opportunity, and motivation, categorizing them with TDF domains.Themes mapped onto the COM-B model and TDF included:Capability: educational barriers to HPV vaccination, unclear post treatment HPV vaccination guidelines.Motivation: beliefs about the importance of HPV vaccination, concerns about the blurred scope of practice.Opportunity: included environmental context and resource barriers at the hospital or clinic level, with concerns related to hospital administration, time concerns, and clinical workflow integration.Highlighted challenges including lack of training in vaccination guidelines, uncertainty about the timing of post-treatment vaccination, concerns about clinic workflow integration, and issues related to the scope of practice for oncology providers.Emphasized the unique role of oncology providers in delivering effective HPV vaccination recommendation to cancer survivors.Kacew et al. (2021)35Zoom interview (due to COVID-19 pandemic),30-minute qualitative interview (structured) with the primary care and specialty clinicians – topics included clinical priorities and roles with cancer survivors, clinician knowledge of HPV vaccine labeling and perceived barriers to vaccination.Primary care clinicians were universally acknowledged for the responsibilities of HPV vaccination.Both primary and oncology clinicians believed unclear and inconsistent HPV vaccination guidelines contributing to uncertainty regarding timing and role of vaccination after completion of cancer treatment.HPV vaccination not being consistently offered to cancer survivors and communication challenges between oncology and primary care clinicians.Need for direct guidance from oncology to both primary care clinicians and patients.Highlighted the burden of unclear and inconsistent guidelines, and importance of better collaboration between primary care and oncology clinicians to improve vaccination.Prioritization of HPV vaccination for survivors among oncology clinicians could reduce uncertainty about vaccination among primary care clinicians. Showing methods, findings, and highlights of the included studies regarding HPV vaccination in childhood cancer survivors. Gender differences: male survivors were 50% less likely to initiate or complete the vaccination than female survivors. Gender differences: male survivors were 50% less likely to initiate or complete the vaccination than female survivors. Survivors from rural location were 50% less likely to initiate and 80% less likely to complete the vaccination than survivors from urban location. Lower initiation in rural survivors (IIR = 0.5, 95% CI: 0.26–0.84) than urban. Survivors from rural location were 50% less likely to initiate and 80% less likely to complete the vaccination than survivors from urban location. Lower initiation in rural survivors (IIR = 0.5, 95% CI: 0.26–0.84) than urban. Cancer diagnosis type: survivors diagnosed with a solid tumor were almost two times more likely to initiate vaccination than diagnosed with epithelial cancer. Cancer diagnosis type: survivors diagnosed with a solid tumor were almost two times more likely to initiate vaccination than diagnosed with epithelial cancer. Between survivors and controls, Hispanic survivors were 50% less likely to initiate or complete the vaccination than Hispanic individuals in controls. Between survivors and controls, Hispanic survivors were 50% less likely to initiate or complete the vaccination than Hispanic individuals in controls. Highlighted disparities in vaccination according to survivors’ gender, location, and type of cancer diagnosis. Highlighted disparities in vaccination according to survivors’ gender, location, and type of cancer diagnosis. Also, identified lower initiation for Hispanic survivors, despite the higher rates in the general Hispanic population suggested potential healthcare access and survivorship care disparities. Also, identified lower initiation for Hispanic survivors, despite the higher rates in the general Hispanic population suggested potential healthcare access and survivorship care disparities. Misconceptions of HPV vaccine was prevalent among caregivers, including belief that it is primarily for females or linked to sexual activity. Misconceptions of HPV vaccine was prevalent among caregivers, including belief that it is primarily for females or linked to sexual activity. Survivors’ knowledge gap regarding the HPV vaccine. Survivors’ knowledge gap regarding the HPV vaccine. Strong recommendations and counseling from trusted specialty group. Strong recommendations and counseling from trusted specialty group. Emphasized critical role of physician counseling in influencing HPV vaccination decisions. Emphasized critical role of physician counseling in influencing HPV vaccination decisions. Showed need for targeted communication strategies to address knowledge gaps and enhance HPV vaccine uptake. Showed need for targeted communication strategies to address knowledge gaps and enhance HPV vaccine uptake. 71.4% of 301 survivors refused due to safety concerns, vaccine hesitancy, external influences, information deficits, and health beliefs/family decisional processes. 71.4% of 301 survivors refused due to safety concerns, vaccine hesitancy, external influences, information deficits, and health beliefs/family decisional processes. Females were more likely to refuse for reasons related to health beliefs/family decisional processes (OR = 2.08, p = .022) and less likely to refuse due to external influences (OR = 0.43, p = .035) than males. Females were more likely to refuse for reasons related to health beliefs/family decisional processes (OR = 2.08, p = .022) and less likely to refuse due to external influences (OR = 0.43, p = .035) than males. Five primary reasons for HPV vaccine refusal among young cancer survivors: safety concerns, vaccine hesitancy, external influences, vaccine-related information deficits, and health beliefs and family decision making process. Five primary reasons for HPV vaccine refusal among young cancer survivors: safety concerns, vaccine hesitancy, external influences, vaccine-related information deficits, and health beliefs and family decision making process. Gender differences: Time to initiate HPV vaccine was 5.7 years for males and 5.5 years for females. Those who initiated, 43.3% males and 55.1% females completed three-dose series, with males taking longer time to complete the vaccination. Gender differences: Time to initiate HPV vaccine was 5.7 years for males and 5.5 years for females. Those who initiated, 43.3% males and 55.1% females completed three-dose series, with males taking longer time to complete the vaccination. Age at cancer diagnosis: older age (6–9 years), vs. < 6 years, were more likely to initiate HPV vaccination for male survivors [HR = 2.13, p = .04] and female [HR = 1.15, p = .609]; however, for female the finding was not significant. Age at cancer diagnosis: older age (6–9 years), vs. < 6 years, were more likely to initiate HPV vaccination for male survivors [HR = 2.13, p = .04] and female [HR = 1.15, p = .609]; however, for female the finding was not significant. Reasons for less likely to initiate the vaccine: Being 18–26 years old at vaccine eligibility (HR = 0.04, 95% CI 0.01–0.16 and males who received blood transfusions during treatment (HR = 0.38, 95% CI 0.18–0.83). Reasons for less likely to initiate the vaccine: Being 18–26 years old at vaccine eligibility (HR = 0.04, 95% CI 0.01–0.16 and males who received blood transfusions during treatment (HR = 0.38, 95% CI 0.18–0.83). Difference in HPV vaccination according to gender, age at vaccine eligibility, types of cancer diagnosed, and cancer treatment. Difference in HPV vaccination according to gender, age at vaccine eligibility, types of cancer diagnosed, and cancer treatment. Among survivors, chemotherapy treatment was associated with a higher rate of missed opportunities (IRR = 1.35, 95% CI: 1.12, 1.62). Among survivors, chemotherapy treatment was associated with a higher rate of missed opportunities (IRR = 1.35, 95% CI: 1.12, 1.62). Age at diagnosis [i.e., diagnosed at older age: IRR = 1.04, 95% CI: 1.02, 1,06] and survivors living in rural area [IRR = 1.27, 95% CI: 1.09, 1.49] were also associated with higher rates of missed opportunities. Age at diagnosis [i.e., diagnosed at older age: IRR = 1.04, 95% CI: 1.02, 1,06] and survivors living in rural area [IRR = 1.27, 95% CI: 1.09, 1.49] were also associated with higher rates of missed opportunities. Higher missed opportunities related to HPV vaccination in cancer survivors suggests need of interventions to increase HPV vaccination among survivors, especially, from rural area. Higher missed opportunities related to HPV vaccination in cancer survivors suggests need of interventions to increase HPV vaccination among survivors, especially, from rural area. Participants expressed insufficient information about the HPV vaccine, worries about safety and side effects for cancer survivors, and concerns about its appropriateness for cancer survivors. Participants expressed insufficient information about the HPV vaccine, worries about safety and side effects for cancer survivors, and concerns about its appropriateness for cancer survivors. Recommendations from trusted providers, including oncologists, were crucial for vaccination initiation. Recommendations from trusted providers, including oncologists, were crucial for vaccination initiation. Most participants preferred to receive recommendations from their cancer team, typically their oncologist. Most participants preferred to receive recommendations from their cancer team, typically their oncologist. Reminders, preferably digital messages, were mentioned to be helpful, with multimedia messages. Reminders, preferably digital messages, were mentioned to be helpful, with multimedia messages. Highlighted the important role of oncology providers in providing information regarding the appropriateness of the vaccine for cancer survivors. Highlighted the important role of oncology providers in providing information regarding the appropriateness of the vaccine for cancer survivors. Caregivers without intent to vaccinate their child held fewer beliefs in protective and necessary aspects of vaccines than those with vaccine intentions. Caregivers without intent to vaccinate their child held fewer beliefs in protective and necessary aspects of vaccines than those with vaccine intentions. Recommendations from healthcare providers increased the likelihood of vaccine intention (oncologist RR = 1.65, p < .01, PCP RR = 1.51, p < .01). Recommendations from healthcare providers increased the likelihood of vaccine intention (oncologist RR = 1.65, p < .01, PCP RR = 1.51, p < .01). Greater time since diagnosis was associated with vaccine intention. Greater time since diagnosis was associated with vaccine intention. Barriers included uncertainty about needed vaccines, concerns about safety and side effects. Barriers included uncertainty about needed vaccines, concerns about safety and side effects. Highlighted that the caregivers who had discussed vaccines with a provider (either with oncology or primary care) were more likely to initiate vaccination. Highlighted that the caregivers who had discussed vaccines with a provider (either with oncology or primary care) were more likely to initiate vaccination. 73% reported a lack of healthcare provider recommendation for the HPV vaccine. 73% reported a lack of healthcare provider recommendation for the HPV vaccine. Perceived lack of insurance coverage (OR = 4.0, p < .001), male sex (OR = 2.8, < 0.001), and decreased parent-survivor communication (OR = 1.6, p = .003), were identified as factors for less likely receiving a provider recommendation for the vaccine. Perceived lack of insurance coverage (OR = 4.0, p < .001), male sex (OR = 2.8, < 0.001), and decreased parent-survivor communication (OR = 1.6, p = .003), were identified as factors for less likely receiving a provider recommendation for the vaccine. Age-stratified analyses showed lack of recommendation, with perceived lack of insurance and male sex remaining significant in both younger and older participants. Age-stratified analyses showed lack of recommendation, with perceived lack of insurance and male sex remaining significant in both younger and older participants. Highlighted the importance of insurance coverage, adequate and timely communication, and demographic including gender-specific considerations in healthcare provider recommendations for HPV vaccination among young cancer survivors. Highlighted the importance of insurance coverage, adequate and timely communication, and demographic including gender-specific considerations in healthcare provider recommendations for HPV vaccination among young cancer survivors. Gender differences: age at vaccine initiation, mean (SD): for female was 15 (2.9) years and for male was 15.5 (3.3) years. Among < 18 years: HPV vaccine initiation incidence among females was 48.1% at 8.2 years, and males was 29.2% at 5.0 years among those < 18 years. Among those ≥18 years: 6.2% among females at 8.1 years and 2.0% among males at 4.2 years. Among those who initiated, 53% females and 43% males completed a 3-dose series. Gender differences: age at vaccine initiation, mean (SD): for female was 15 (2.9) years and for male was 15.5 (3.3) years. Among < 18 years: HPV vaccine initiation incidence among females was 48.1% at 8.2 years, and males was 29.2% at 5.0 years among those < 18 years. Among those ≥18 years: 6.2% among females at 8.1 years and 2.0% among males at 4.2 years. Among those who initiated, 53% females and 43% males completed a 3-dose series. Younger age at cancer diagnosis and shorter interval from diagnosis to vaccine eligibility were more likely to initiate the vaccination. Younger age at cancer diagnosis and shorter interval from diagnosis to vaccine eligibility were more likely to initiate the vaccination. Age at cancer diagnosis emerged as a significant predictor, with younger survivors more likely to initiate vaccination. Age at cancer diagnosis emerged as a significant predictor, with younger survivors more likely to initiate vaccination. Time from cancer diagnosis negatively influenced vaccine initiation, emphasizing the need for timely intervention during pediatric oncology and survivorship care. Time from cancer diagnosis negatively influenced vaccine initiation, emphasizing the need for timely intervention during pediatric oncology and survivorship care. Factors for increased HPV vaccine intent included provider recommendation (OR = 5.0; p = .01), positive attitude toward vaccines (OR = 4.8; p < .001), and perceived severity of HPV-related illness (OR = 3.5; p = .02). Factors for increased HPV vaccine intent included provider recommendation (OR = 5.0; p = .01), positive attitude toward vaccines (OR = 4.8; p < .001), and perceived severity of HPV-related illness (OR = 3.5; p = .02). The intent to receive the HPV vaccine is influenced by healthcare provider recommendations and positive attitudes toward the vaccines. The intent to receive the HPV vaccine is influenced by healthcare provider recommendations and positive attitudes toward the vaccines. Common reasons for refusal were not having enough information on HPV vaccine (25.2%), child not being the right age (22.7%), and worries about side effects (21.9). Common reasons for refusal were not having enough information on HPV vaccine (25.2%), child not being the right age (22.7%), and worries about side effects (21.9). Enough information from providers regarding vaccine and side effects (relative risk (RR) = 1.85, 95% CI 1.16–2.94) and recommendations regarding vaccines after cancer treatment (RR = 1.35, 95% CI: 1.06–1.72) showed greater caregiver intention to get the HPV vaccine for their child. Enough information from providers regarding vaccine and side effects (relative risk (RR) = 1.85, 95% CI 1.16–2.94) and recommendations regarding vaccines after cancer treatment (RR = 1.35, 95% CI: 1.06–1.72) showed greater caregiver intention to get the HPV vaccine for their child. Enough information (vaccine, benefits, and side effects) from providers positively influenced caregivers’ intention to vaccinate their child. Enough information (vaccine, benefits, and side effects) from providers positively influenced caregivers’ intention to vaccinate their child. Predictors of non-initiation of HPV vaccine included lack of provider recommendation (OR = 10.8, p < .001), survivors’ perceived lack of insurance coverage (OR = 6.6, p < .001), male sex (OR = 2.9, p < .001), endorsement of vaccine-related barriers (OR = 2.7, p < .001), and younger age (i.e. 9–12 years vs. 13–17 years: OR = 3.7, p < .001). Predictors of non-initiation of HPV vaccine included lack of provider recommendation (OR = 10.8, p < .001), survivors’ perceived lack of insurance coverage (OR = 6.6, p < .001), male sex (OR = 2.9, p < .001), endorsement of vaccine-related barriers (OR = 2.7, p < .001), and younger age (i.e. 9–12 years vs. 13–17 years: OR = 3.7, p < .001). Among those who received a provider recommendation, predictors of vaccine non-initiation included lack of insurance coverage (OR = 7.5, p < .001) and younger age (OR = 5.0, p < .001). Among those who received a provider recommendation, predictors of vaccine non-initiation included lack of insurance coverage (OR = 7.5, p < .001) and younger age (OR = 5.0, p < .001). Predictors for non-initiation included lack of provider recommendation, lack of insurance, endorsement of vaccine-related barriers and younger age. Predictors for non-initiation included lack of provider recommendation, lack of insurance, endorsement of vaccine-related barriers and younger age. Highlights the importance of provider recommendation. Highlights the importance of provider recommendation. Physician recommendation (OR = 11.24, p < .001) and familial HPV communication (OR = 7.28, p = .01) were positively associated with vaccine initiation. Physician recommendation (OR = 11.24, p < .001) and familial HPV communication (OR = 7.28, p = .01) were positively associated with vaccine initiation. Perception of vaccine benefit was associated with vaccine completion (OR = 10.55, p = .02), whereas perception of vaccine severity was associated with non-completion (OR = 0.14, p = .02). Perception of vaccine benefit was associated with vaccine completion (OR = 10.55, p = .02), whereas perception of vaccine severity was associated with non-completion (OR = 0.14, p = .02). Highlighted that the physician recommendation for HPV vaccine as a strong predictor of vaccine initiation and completion in cancer survivors. Highlighted that the physician recommendation for HPV vaccine as a strong predictor of vaccine initiation and completion in cancer survivors. Initiation rate varied by age group, with preadolescents having lower initiation rate (19.5%) than adolescents (45.3%) and young adults (38.6%). Initiation rate varied by age group, with preadolescents having lower initiation rate (19.5%) than adolescents (45.3%) and young adults (38.6%). Older age at diagnosis (≥12 years) [OR = 0.28, p = .01] was associated with lower vaccine initiation and provider recommendation [OR = 11.96, p < .001] was associated with higher vaccine initiation. Older age at diagnosis (≥12 years) [OR = 0.28, p = .01] was associated with lower vaccine initiation and provider recommendation [OR = 11.96, p < .001] was associated with higher vaccine initiation. Regarding vaccine completion: non-White participants were less likely to complete [OR = 0.17, p = .01], and receiving physician recommendation [OR = 7.54, p = .03] were more likely to complete. Regarding vaccine completion: non-White participants were less likely to complete [OR = 0.17, p = .01], and receiving physician recommendation [OR = 7.54, p = .03] were more likely to complete. Highlighted the age group disparities with the preadolescents showing lower HPV vaccine initiation rates than adolescents and young adults. Highlighted the age group disparities with the preadolescents showing lower HPV vaccine initiation rates than adolescents and young adults. Physician recommendation emerged as a key predictor for vaccine initiation across all age groups. Physician recommendation emerged as a key predictor for vaccine initiation across all age groups. Older daughter’s age (OR = 5.82; 95% CI: 2.00–16.91) and physician recommendation (OR = 6.54; 95% CI: 2.56–16.73) were associated with increased vaccine initiation. Older daughter’s age (OR = 5.82; 95% CI: 2.00–16.91) and physician recommendation (OR = 6.54; 95% CI: 2.56–16.73) were associated with increased vaccine initiation. Mothers who perceived greater barriers (financial or religious, fears that vaccine promoting sexual activity, general lack of support for vaccination) were less likely to start the vaccination for their daughters. Mothers who perceived greater barriers (financial or religious, fears that vaccine promoting sexual activity, general lack of support for vaccination) were less likely to start the vaccination for their daughters. Among those who initiated, risk factors for noncompletion included being non-White (OR = 0.26, p = .032) and perceiving barriers to vaccination (OR = 0.21, 0.015). Among those who initiated, risk factors for noncompletion included being non-White (OR = 0.26, p = .032) and perceiving barriers to vaccination (OR = 0.21, 0.015). Older age of the daughter and receiving recommendation from healthcare provider showed increased vaccine initiation. Older age of the daughter and receiving recommendation from healthcare provider showed increased vaccine initiation. Age differences: overall rate for HPV vaccination (1 or more) was 5% among ages 11–12 years, 36% for 13–17 years, and 78% among 18 years. Age differences: overall rate for HPV vaccination (1 or more) was 5% among ages 11–12 years, 36% for 13–17 years, and 78% among 18 years. Hesitancy about HPV vaccine safety and side effects. Hesitancy about HPV vaccine safety and side effects. Factors positively associated with vaccination: age ≥13, report of sexual activity, and discussed about HPV vaccination with health care providers. Factors positively associated with vaccination: age ≥13, report of sexual activity, and discussed about HPV vaccination with health care providers. Highlighted that the survivors ages ≥13 years were more likely to initiate HPV vaccine series than their younger counterparts. Highlighted that the survivors ages ≥13 years were more likely to initiate HPV vaccine series than their younger counterparts. 47% providers mentioned communication with patients about HPV vaccination, 69% expressed willingness to become involved in vaccine delivery. 47% providers mentioned communication with patients about HPV vaccination, 69% expressed willingness to become involved in vaccine delivery. Perceived barriers included roles outside clinical care, competing priorities, provider knowledge gaps, and patient- and family- related factors (e.g., patient being too young for vaccination, hesitancy, knowledge gap, family preference), and system-level (e.g., HPV vaccine not included in clinical setting like COVID-19 or influenza vaccine, access to HPV vaccine, delays in processing HPV vaccine). Perceived barriers included roles outside clinical care, competing priorities, provider knowledge gaps, and patient- and family- related factors (e.g., patient being too young for vaccination, hesitancy, knowledge gap, family preference), and system-level (e.g., HPV vaccine not included in clinical setting like COVID-19 or influenza vaccine, access to HPV vaccine, delays in processing HPV vaccine). Providers expressed HPV vaccine delivery to be under the system (e.g., having it available, sending EMR reminders). Providers expressed HPV vaccine delivery to be under the system (e.g., having it available, sending EMR reminders). Opportunities to collaborate between oncology providers and primary care providers. Opportunities to collaborate between oncology providers and primary care providers. Highlighted providers’ willingness to play active roles in HPV vaccine delivery. Highlighted providers’ willingness to play active roles in HPV vaccine delivery. Key potential areas identified included access and coordination of vaccine administration, engaging in cancer prevention education, and advocating for HPV vaccination during transitions in care. Key potential areas identified included access and coordination of vaccine administration, engaging in cancer prevention education, and advocating for HPV vaccination during transitions in care. 90% recognized the importance of HPV vaccination for their patient population, with 65% expressing no concerns about the vaccine. 90% recognized the importance of HPV vaccination for their patient population, with 65% expressing no concerns about the vaccine. The primary motivation for recommending HPV vaccination was cancer prevention (80%). The primary motivation for recommending HPV vaccination was cancer prevention (80%). 75% believed that the responsibility for HPV vaccination should fall under the PCP care. 75% believed that the responsibility for HPV vaccination should fall under the PCP care. Barriers: patient-level: concerns about promoting sexual activity and worries about side effects; clinician-level: lack of updated information and awareness of available vaccines; system-level: time constraints, inadequate nursing/medical assistant resources, difficulties accessing vaccine records, vaccine accessibility, storage limitations, cost, and reimbursement challenges. Barriers: patient-level: concerns about promoting sexual activity and worries about side effects; clinician-level: lack of updated information and awareness of available vaccines; system-level: time constraints, inadequate nursing/medical assistant resources, difficulties accessing vaccine records, vaccine accessibility, storage limitations, cost, and reimbursement challenges. Highlighted that majority providers recognized the importance of HPV vaccination; however, clinicians faced challenges in accessing information, vaccine availability, and time constraints. Highlighted that majority providers recognized the importance of HPV vaccination; however, clinicians faced challenges in accessing information, vaccine availability, and time constraints. Showed importance of multi-level interventions, including patient-level, provider-level, and system-level, to improve HPV vaccination coverage. Showed importance of multi-level interventions, including patient-level, provider-level, and system-level, to improve HPV vaccination coverage. Themes mapped onto the COM-B model and TDF included: Themes mapped onto the COM-B model and TDF included: Capability: educational barriers to HPV vaccination, unclear post treatment HPV vaccination guidelines. Capability: educational barriers to HPV vaccination, unclear post treatment HPV vaccination guidelines. Motivation: beliefs about the importance of HPV vaccination, concerns about the blurred scope of practice. Motivation: beliefs about the importance of HPV vaccination, concerns about the blurred scope of practice. Opportunity: included environmental context and resource barriers at the hospital or clinic level, with concerns related to hospital administration, time concerns, and clinical workflow integration. Opportunity: included environmental context and resource barriers at the hospital or clinic level, with concerns related to hospital administration, time concerns, and clinical workflow integration. Highlighted challenges including lack of training in vaccination guidelines, uncertainty about the timing of post-treatment vaccination, concerns about clinic workflow integration, and issues related to the scope of practice for oncology providers. Highlighted challenges including lack of training in vaccination guidelines, uncertainty about the timing of post-treatment vaccination, concerns about clinic workflow integration, and issues related to the scope of practice for oncology providers. Emphasized the unique role of oncology providers in delivering effective HPV vaccination recommendation to cancer survivors. Emphasized the unique role of oncology providers in delivering effective HPV vaccination recommendation to cancer survivors. Primary care clinicians were universally acknowledged for the responsibilities of HPV vaccination. Primary care clinicians were universally acknowledged for the responsibilities of HPV vaccination. Both primary and oncology clinicians believed unclear and inconsistent HPV vaccination guidelines contributing to uncertainty regarding timing and role of vaccination after completion of cancer treatment. Both primary and oncology clinicians believed unclear and inconsistent HPV vaccination guidelines contributing to uncertainty regarding timing and role of vaccination after completion of cancer treatment. HPV vaccination not being consistently offered to cancer survivors and communication challenges between oncology and primary care clinicians. HPV vaccination not being consistently offered to cancer survivors and communication challenges between oncology and primary care clinicians. Need for direct guidance from oncology to both primary care clinicians and patients. Need for direct guidance from oncology to both primary care clinicians and patients. Highlighted the burden of unclear and inconsistent guidelines, and importance of better collaboration between primary care and oncology clinicians to improve vaccination. Highlighted the burden of unclear and inconsistent guidelines, and importance of better collaboration between primary care and oncology clinicians to improve vaccination. Prioritization of HPV vaccination for survivors among oncology clinicians could reduce uncertainty about vaccination among primary care clinicians. Prioritization of HPV vaccination for survivors among oncology clinicians could reduce uncertainty about vaccination among primary care clinicians. Results Twenty studies were included in this review (Tables 2 and 3). Descriptive characteristics of the participants in the original studies included are shown in Table 2 and Figure 2. Across the 20 studies, 169,10,20–33 (80%) included cancer survivors and/or their caregivers to understand factors influencing HPV vaccination and four studies34–37 (20%) included health care providers to understand their perspectives and roles pertaining to HPV vaccination among cancer survivors. Participants in the original studies were mainly non-Hispanic White followed by Black and Hispanic populations. The included studies covered a broad range of childhood cancers, most commonly leukemia, followed by lymphoma and other solid tumors, including central nervous system (CNS) tumors. Within four studies (20%) that focused on health care providers perspectives,34–37 the majority of the providers were non-Hispanic White, and were mainly pediatric oncology or hematology providers; one study included primary care providers along with pediatric oncology clinicians. Details regarding participant demographics are summarized in Table 2. Characteristics of the participants across the included studies. Table 3 shows the findings from the included studies (n = 20) focusing on barriers and facilitators categorized by the perspectives of: 1) childhood cancer survivors and caregivers and 2) health care providers. Figures 3 and Figure 4 further summarize these barriers and facilitators reported across the included studies. Barriers (B) and facilitators (F) influencing HPV vaccination among childhood cancer survivors based on included quantitative studies. Barriers (B) and facilitators (F) influencing HPV vaccination among childhood cancer survivors reported across the studies. Childhood cancer survivors and caregivers Barriers for HPV vaccination Several barriers to HPV vaccination were endorsed by cancer survivors and caregivers including insufficient communication from health care providers (included in eight studies),9,25–29,32,33 vaccine knowledge gaps (included in seven studies),10,25,26,29,31,32,35 worries about vaccine side effects (included in four studies),23,35,31,32 vaccine safety concerns (included in three studies),10,31,32 vaccine misperception (included in three studies),26,29,36 vaccine hesitancy (included in two studies),10,23 uncertainty about benefits of HPV vaccine in cancer survivors (included in two studies),31,32 financial barriers (included in two studies),9,26 survivors from rural location (included in two studies),24,30 and family decision-making processes (included in one study).10 Cancer survivors and caregivers expressed concerns about the HPV vaccine safety and side effects.10,23,25,31,32 They also expressed hesitancy to receive the HPV vaccine and the need for more time before making decisions regarding vaccination.10,23 Additionally, they relayed knowledge gaps, such as the misperception that the HPV vaccine was indicated only for sexually active individuals.26,29 Caregivers who perceived financial and/or religious barriers, or fear of the vaccine promoting sexual activity, were less likely to initiate the vaccination for their daughters.26,37 Cancer survivors and caregivers’ perceptions that HPV vaccination was only for females or that the vaccine was linked to sexual activity hindered vaccination efforts.29 Health beliefs and family decision-making processes played critical roles in HPV vaccine acceptance.10 Family decision-making processes were more likely to influence the receipt of vaccination for female cancer survivors than male cancer survivors.10 Furthermore, male cancer survivors took longer time to initiate the HPV vaccination than females.20,22,24 Lack of understanding about the cancer prevention benefits of HPV vaccination was identified.31 Caregivers also reported insufficient information about the appropriateness of HPV vaccination for cancer survivors.31,32 Lack of effective communication and recommendations regarding HPV vaccination from health care providers were also observed as barriers in several studies.9,25–29,32,33 A few studies observed relationships between HPV vaccination in cancer survivors and cancer-specific factors.22,30,31 One study observed a lower prevalence of HPV vaccination in cancer survivors of CNS tumors and those who received blood transfusions.22 Another study showed cancer survivors treated with chemotherapy had higher vaccination missed opportunities.30 Additionally, the time elapsed since a cancer diagnosis also influenced HPV vaccination, with longer time since cancer diagnosis correlating with greater vaccine intention.22,31 Table 2.(Continued).Author (publication year)Study aimStudy sampleRace/EthnicityAge (years)Area of specialtyYears in practiceNumber of survivors seen by providerWaters et al. (2023)37To conduct qualitative interviews with adult and pediatric oncology providers at two large, academically affiliated hospitals, aiming to gain insights into their perspectives on providing HPV vaccination in oncology setting, characterize their approach to providing vaccine, and explore barriers to delivery and considerations to providing the vaccine in oncology settings.Total oncology providers = 24NAProvider direct patient care:Yes = 21; No (operations focused) = 3Area of specialty:Bone marrow transplant = 4; Medical oncology = 4; Nurse coordination = 4; pediatric oncology = 5; pharmacy = 1; radiation oncology = 1; surgery = 4; survivorship care = 1 Kacew et al. (2021)35To understand clinician-level (primary care and oncology clinicians) barriers to providing HPV vaccination to survivors of childhood and young adult cancers (CYACs).Total = 24NANAAdult primary care clinicians = 5Pediatric primary care clinicians = 6Pediatric oncology clinicians = 4Adult oncology clinicians = 5Fellows in pediatric oncology = 4Median:Adult primary care clinicians = 12Pediatric primary care clinicians = 13Pediatric oncology clinicians = 9Adult oncology clinicians = 26Fellows in pediatric oncology = 3Survivors seen per year (Median):Adult primary care clinicians = 1.5Pediatric primary care clinicians = 5Pediatric oncology clinicians = 10Adult oncology clinicians = 12Fellows in pediatric oncology = 6 (Continued). Facilitators for HPV vaccination Across the included studies, facilitators for HPV vaccination also were identified. Facilitators were identified by cancer survivors and caregivers, most notably health care provider recommendation along with access to information about HPV vaccination. A strong predictor of HPV vaccination was the recommendation from a health care provider, which drove acceptance of HPV vaccination among cancer survivors and caregivers.9,21,28 Adequate and acceptable HPV vaccination information, such as information about the HPV vaccine and its potential side effects, coupled with a provider recommendation for vaccination after completion of cancer treatment showed greater intention among caregiver to agree to HPV vaccination for their child.21,25,26,28 Additionally, positive attitude toward HPV vaccination and perceived severity of HPV-related illnesses, including HPV-associated cancers, facilitated uptake among cancer survivors.21 Cancer survivors and their caregivers who perceived HPV vaccine benefit were most likely to complete HPV vaccination.28 Health care providers’ perspectives Barriers for HPV vaccination Healthcare provider perceptions regarding the HPV vaccination for cancer survivors revealed several barriers that influenced vaccine uptake including the combination of access to and understanding of clear and consistent guidelines, time constraints, competing priorities, patient-level concerns, and system-level challenges. Several studies observed that unclear and inconsistent guidelines for HPV vaccination for cancer survivors created challenges to effective communication about HPV vaccination among health care providers.35–37 Health care providers endorsed inconsistency in providing recommendations for HPV vaccination due to the lack of clarity and consistency in HPV vaccination guidelines after cancer treatment, and inadequate communication between oncology and primary care clinicians.35–37 Other barriers included gaps in provider knowledge regarding HPV vaccine guidelines specific to cancer survivors.34 Additionally, time constraints and competing clinical priorities prevented oncology health care providers from discussing HPV vaccination with cancer survivors and caregivers.34,36,37 Limited time during appointments often hindered detailed communication about HPV vaccination.36 Additionally, oncology health care providers reported inadequate resources, such as insufficient medical/nurse staff to focus on vaccination, which further limited their ability to recommend and provide HPV vaccine to cancer survivors during appointments.36 Furthermore, oncology clinicians perceived that the vaccination was within the scope of care of primary care clinicians.35,36 Health care providers also acknowledged that cancer survivors’ hesitancy surrounding HPV vaccination may be related to the perception that HPV vaccination promotes sexual activity.36 Providers also reported barriers, such as patient fears and worries about HPV vaccine side effects.36 Health care providers recognized that the cancer survivors’ concerns need to be addressed to improve HPV vaccination uptake but reported challenges to finding effective ways to alleviate fears and misconceptions during clinical interactions.37 Some studies described perspectives of oncology health care providers about barriers at the system-level.34,36,37 Providers reported systematic challenges, such as difficulties accessing vaccination records and lack of availability of HPV vaccine in oncology clinical settings compared to other vaccines for COVID-19 or flu.34,36 Issues with the availability of the HPV vaccine and inadequate space for HPV vaccination storage were also mentioned.37 Facilitators for HPV vaccination Facilitators for HPV vaccination from the perspectives of health care providers were identified in the included studies. When oncology care providers are generally positive about HPV vaccination for young cancer survivors and are willing to communicate about HPV vaccine with cancer survivors and their caregivers, vaccine uptake improves.34 Additionally, health care providers knowledge, understanding, and beliefs about the importance of HPV vaccination for cancer survivors facilitated HPV vaccination for cancer survivors.36 Recommended potential strategies to improve HPV vaccination Eleven included studies (55%) reported potential strategies to improve HPV vaccination coverage among cancer survivors. These included vaccine recommendation from health care providers,9,23,25,27,28,29,31,33,34,35 particularly from trusted members of the oncology care team,25,29,31 and sending reminders, preferably digital messages for timely vaccination.32,34 Health care providers also emphasized the importance of system-level solutions, such as having the HPV vaccine readily available during cancer survivor visits, integrating reminders into the electronic medical record, and mechanisms to foster timely collaboration and communication between oncology and primary care providers.34 Discussion This scoping review study identified barriers and facilitators to HPV vaccination among cancer survivors. According to results published in included studies, cancer survivors and their caregivers identified key barriers for HPV vaccination, which included concerns about inadequate information about vaccine safety data, vaccine hesitancy, an understanding of the influence of health beliefs and family decision-making on vaccine uptake, and the lack of HPV vaccination communication and recommendation from health care providers. HPV vaccination uptake was also associated with cancer-specific factors, such as cancer type, cancer treatment received and time since cancer treatment completion. Cancer survivors with a history of brain cancer, for example, and those who received chemotherapy were less likely to be vaccinated. However, longer time since cancer treatment was linked to greater vaccine intention. Facilitators of HPV vaccination included health care provider recommendations, positive caregiver attitudes and awareness of HPV-related illness and severity. From the perceptive of health care providers, the results of included studies identified barriers for HPV vaccination among childhood cancer survivors, such as unclear and inconsistent HPV vaccination guidelines, competing clinical priorities, time constraints, and system-level challenges, including ready access to HPV vaccine doses for administration. Unclear post-treatment vaccination protocols have caused confusion, making it difficult for providers to communicate effectively about HPV vaccination. Though the providers acknowledged the importance of HPV vaccination, they faced challenges in effectively communicating HPV vaccination information to cancer survivors, suggesting a need for standardized and clear protocols/guidelines regarding HPV vaccination specific to the cancer survivors. In included studies, oncologists also reported system-level barriers, such as lack of vaccine availability and limited storage, hindering HPV vaccine implementation within oncology care settings where survivors and caregivers emphasize high levels of trust. These data highlight the need for supportive infrastructures within the clinical care setting to promote timely receipt of the HPV vaccine for cancer survivors. Furthermore, primary care clinicians were acknowledged by other providers for their important role in vaccination. However, studies showed primary care clinicians lack adequate guidelines for HPV vaccination for cancer survivors. Enhanced collaboration between oncology and primary care providers, along with shared guidelines and clear communication, could help to improve HPV vaccination coverage in this under-vaccinated population. Health care providers also acknowledged patient-level concerns, such as vaccine safety, hesitancy, and the misconception that HPV vaccination promotes sexual activity. These concerns were also prevalent among cancer survivors and their caregivers, emphasizing the need for tailored communication strategies to effectively address patient and caregiver-level concerns. As the cancer survivors and their families trust the oncology care team for health-related guidance, addressing these concerns directly by the oncology care team could potentially increase HPV vaccination coverage. Strategies to improve awareness by framing conversations about HPV vaccination as cancer prevention could alleviate caregivers’ concerns and reduce HPV vaccination hesitancy. The included studies highlighted potential strategies to improve HPV vaccination coverage among cancer survivors. Most emphasized the importance of strong recommendations from trusted health care providers, particularly from oncology care teams. Cancer survivors and their caregivers trust their oncology care team to provide health information and prefer to visit their oncologist even for follow-up care.38,39 Utilizing the trusted oncology care team to directly convey HPV vaccination information is a promising potential strategy to increase vaccination coverage among cancer survivors. Additional potential strategies include digital reminders, integrated into electronic medical records, and fostering timely collaboration and communication between patients, caregivers, oncology providers and primary care providers regarding HPV vaccination. The role of oncology care providers emerged as pivotal in influencing HPV vaccination among cancer survivors. Furthermore, after completion of cancer treatment, cancer survivors also visit primary care clinicians within their community.40 This transition from oncology care team to the primary care providers can be challenging without proper coordination. Despite the increased health risk of HPV-associated cancers and other conditions among cancer survivors, there is limited discussion about their cancer and survivorship care plan with their primary care providers.41 As a result, this might create gaps in adequate utilization of available health care services. Effective communication about survivorship care plans, including HPV vaccination, would help cancer survivors to make timely decisions in obtaining health preventive measures. Once HPV vaccination has been initiated, the HPV vaccine series must be completed to ensure maximum protection against HPV-related infections and cancers.42 The updated COG guidelines recommend a three-dose HPV vaccine series for these cancer survivors, starting 6 months after the completion of cancer treatment, regardless of their age at the first dose of the HPV vaccine.6 This change was informed by the robust evidence from the study by Landier et al. which demonstrated the immunogenicity and safety of the three-dose HPV vaccine series in cancer survivors.43 Prior to the guideline updates for HPV vaccination in October 2023, the COG guidelines were to follow the CDC recommendations (i.e., two doses of the HPV vaccine in children who start the vaccine series before their 15th birthday and three doses among those who start the vaccine series on or after 15th birthday and individuals with immunocompromised conditions).44 These HPV vaccination guidelines changes could lead to confusion among young cancer survivors and their caregivers who considered their HPV vaccination series complete after two doses. Thus, this indicates the need for dissemination of clear and detailed guidelines on doses and timing of HPV vaccination for cancer survivors. This review identified the need for multifaceted strategies to address barriers experienced by survivors, their caregivers, and health care providers to improve HPV vaccination coverage among cancer survivors. Understanding the barriers and identifying tailored strategies at multiple levels, including cancer survivors and caregiver-level (such as, addressing knowledge gap, vaccine hesitancy), health care provider-level (such as, clear HPV vaccination guidelines, proper communication and coordination), and system-level (such as, ensuring vaccine availability and adequate storage), are crucial to improve HPV vaccination coverage among cancer survivors and reduce HPV-related cancers among this vulnerable and under-vaccinated population. Childhood cancer survivors often require long-term follow-up care. Implementing comprehensive support programs that address their unique needs, including HPV vaccination, could bridge the gaps during transition from oncology to primary care settings. Multidisciplinary teams, including oncologists, primary care providers, nurses, and other health care professionals, can ensure continuity of care and support informed decision-making for preventive measures like HPV vaccination. Addressing knowledge gaps and misconceptions among cancer survivors and caregivers through targeted communication and counseling can provide clarity on vaccine safety and benefits. Additionally, training health care providers on HPV vaccination guidelines specific to cancer survivors would be valuable. This study provides valuable insights into challenges and potential strategies for improving HPV vaccination among cancer survivors; however, we also acknowledge some limitations. First, we initially intended to include original studies describing actual interventions, programs, or strategies to improve HPV vaccination coverage among childhood cancer survivors. Due to limited studies focusing on interventions to improve HPV vaccination coverage among cancer survivors, we included studies focusing on barriers and facilitators to HPV vaccination among cancer survivors. Second, we only included the original research articles but did not include the gray literature and may have missed important relevant information. Third, the included original studies may not represent the entire population of cancer survivors, as they were limited to specific geographical regions and health care settings, which may limit the applicability of the findings to the broader population of cancer survivors. Fourth, the heterogeneity among the included studies in terms of their outcome measures and sample sizes makes it difficult to directly compare the findings across the studies. Fifth, we included only the studies conducted in the U.S., which might limit the generalizability of the findings to other countries. Conclusion This review study identified key barriers and facilitators influencing HPV vaccination among cancer survivors, emphasizing the critical role of health care providers, particularly oncologists, in promoting HPV vaccination through strong recommendations and clear communication. Findings support the importance of health care providers considering patient and caregiver safety concerns, health beliefs, and family decision-making strategies when communicating the importance of HPV vaccination. Implementation work is needed to broadly distribute the current HPV vaccination guidelines to both oncologists and primary care providers, and to determine how best to address competing clinical priorities, time constraints, and system-level challenges. Addressing challenges through coordinated and multidisciplinary strategies is essential to improve HPV vaccination coverage and reduce the risk of HPV-related cancers among this vulnerable and under-vaccinated population. Acknowledgments All authors have read and agreed to the published version of the manuscript. Biography Heather M. Brandt, PhD directs the HPV Cancer Prevention Program at St. Jude Children’s Research Hospital. She is co-associate director for outreach in the St. Jude Comprehensive Cancer Center and full faculty member in the Department of Epidemiology and Cancer Control. As a social and behavioral and public health implementation scientist, her research and implementation activities focus on cancer-related health disparities in cancer prevention and control and specifically on working with those who have professional and lived experiences as subject matter experts, thought leaders, partners, and allies to effectively use what we know works to increase HPV vaccination coverage. She is the recipient of several awards, including the 2023 Leadership in HPV Vaccination Award from the American Cancer Society (ACS) National HPV Vaccination Roundtable. Funding Statement This project was supported by the American Lebanese and Syrian Associated Charities (ALSAC) of St. Jude Children’s Research Hospital. Additionally, this work was supported by the National Cancer Institute P30 Cancer Center Support Grant [3P30CA021765-44S3 and 3P30CA021765-45S3]. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement No new data were created in this study. The articles included in this study are available in the PubMed, CINAHL, and Web of Science databases. Ethical statement Ethical approval and informed consent were not required for this review study. Institutional review board statement As this review study is based on already published studies, institutional review board approval was not applicable. References Associated Data Data Availability Statement No new data were created in this study. The articles included in this study are available in the PubMed, CINAHL, and Web of Science databases.